Results from the "Me & My Heart" (eMocial) Study: a Randomized Evaluation of a New Smartphone-Based Support Tool to Increase Therapy Adherence of Patients with Acute Coronary Syndrome

Krackhardt, Florian and Jornten-Karlsson, Magnus and Waliszewski, Matthias and Knutsson, Mikael and Niklasson, Anna and Appel, Karl-Friedrich and Degenhardt, Ralf and Ghanem, Alexander and Koehler, Till and Ohlow, Marc-Alexander and Tschoepe, Carsten and Theres, Heinz and vom Dahl, Juergen and Karlson, Bjorn W. and Maier, Lars S. (2023) Results from the "Me & My Heart" (eMocial) Study: a Randomized Evaluation of a New Smartphone-Based Support Tool to Increase Therapy Adherence of Patients with Acute Coronary Syndrome. CARDIOVASCULAR DRUGS AND THERAPY, 37. pp. 729-741. ISSN 0920-3206, 1573-7241

Full text not available from this repository. (Request a copy)

Abstract

Purpose This study evaluated whether patient support, administered via an electronic device-based app, increased adherence to treatment and lifestyle changes in patients with acute coronary syndrome (ACS) treated with ticagrelor in routine clinical practice. Methods Patients (aged >= 18 years) with diagnosed ACS treated with ticagrelor co-administered with low-dose acetylsalicylic acid were randomized into an active group (with support tool app for medication intake reminders and motivational messages) and a control group (without support tool app), and observed for 48 weeks (ClinicalTrials.gov Identifier: NCT02615704). Patients were asked to complete the 36-item Short-Form Health Survey (SF-36) and Lifestyle Changes Questionnaire (LSQ), and were assessed for blood pressure and body mass index (BMI) at baseline (visit 1) and at the end of the study (visit 2). Medication adherence was measured using the Brilique Adherence Questionnaire (BAQ). Results Patients (N = 676) were randomized to an active (n = 342) or a control (n = 334) group. BAQ data were available for 174 patients in the active group and 174 patients in the control group. Over the 48-week period, mean (standard deviation) adherence for the active and control groups was 96.4% (13.2%) and 91.5% (23.1%), respectively (effect of app intervention, p < 0.05). There were no significant differences in blood pressure and BMI between visits. General improvements in SF-36 and LSQ scores were observed for both groups. Conclusion The patient support tool app was associated with significant improvements in patient-reported treatment adherence compared with a data collection app alone in patients prescribed ticagrelor for ACS.

Item Type: Article
Uncontrolled Keywords: DISEASE; Acute coronary syndrome; Adherence; Dual antiplatelet therapy; Smartphone-based support; Ticagrelor
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin II
Depositing User: Petra Gürster
Date Deposited: 10 Apr 2025 08:16
Last Modified: 10 Apr 2025 08:16
URI: https://pred.uni-regensburg.de/id/eprint/58461

Actions (login required)

View Item View Item